AU2021396509A1 - Cyclobenzaprine treatment for fibromyalgia - Google Patents

Cyclobenzaprine treatment for fibromyalgia Download PDF

Info

Publication number
AU2021396509A1
AU2021396509A1 AU2021396509A AU2021396509A AU2021396509A1 AU 2021396509 A1 AU2021396509 A1 AU 2021396509A1 AU 2021396509 A AU2021396509 A AU 2021396509A AU 2021396509 A AU2021396509 A AU 2021396509A AU 2021396509 A1 AU2021396509 A1 AU 2021396509A1
Authority
AU
Australia
Prior art keywords
cyclobenzaprine
mannitol
eutectic
composition
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021396509A
Other languages
English (en)
Other versions
AU2021396509A9 (en
Inventor
Seth Lederman
Gregory M. Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharmaceuticals Holding Corp
Original Assignee
Tonix Pharmaceuticals Holding Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharmaceuticals Holding Corp filed Critical Tonix Pharmaceuticals Holding Corp
Publication of AU2021396509A1 publication Critical patent/AU2021396509A1/en
Publication of AU2021396509A9 publication Critical patent/AU2021396509A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021396509A 2020-12-07 2021-12-07 Cyclobenzaprine treatment for fibromyalgia Pending AU2021396509A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122469P 2020-12-07 2020-12-07
US63/122,469 2020-12-07
PCT/US2021/062244 WO2022125572A1 (en) 2020-12-07 2021-12-07 Cyclobenzaprine treatment for fibromyalgia

Publications (2)

Publication Number Publication Date
AU2021396509A1 true AU2021396509A1 (en) 2023-06-29
AU2021396509A9 AU2021396509A9 (en) 2024-09-19

Family

ID=79686930

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021396509A Pending AU2021396509A1 (en) 2020-12-07 2021-12-07 Cyclobenzaprine treatment for fibromyalgia

Country Status (9)

Country Link
US (2) US20240024256A1 (https=)
EP (1) EP4255407A1 (https=)
JP (1) JP2023554692A (https=)
CN (1) CN116940340A (https=)
AU (1) AU2021396509A1 (https=)
CA (1) CA3204202A1 (https=)
IL (1) IL303497A (https=)
MX (1) MX2023006720A (https=)
WO (1) WO2022125572A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3260042A1 (en) * 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF A (SARS)-COV-2 (PASC) INFECTION
WO2025137348A1 (en) * 2023-12-19 2025-06-26 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63822B1 (sr) 2012-06-15 2023-01-31 Tonix Pharma Holdings Ltd Kompozicije i postupci za transmukoznu apsorpciju
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
MY186047A (en) * 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
US20220117915A1 (en) * 2018-08-20 2022-04-21 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Also Published As

Publication number Publication date
WO2022125572A1 (en) 2022-06-16
CN116940340A (zh) 2023-10-24
EP4255407A1 (en) 2023-10-11
US20240024256A1 (en) 2024-01-25
JP2023554692A (ja) 2023-12-28
CA3204202A1 (en) 2022-06-16
MX2023006720A (es) 2023-08-18
IL303497A (en) 2023-08-01
US20260108477A1 (en) 2026-04-23
AU2021396509A9 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US20260108477A1 (en) Cyclobenzaprine treatment for fibromyalgia
JP2002539245A5 (https=)
RU2007140348A (ru) Способы и композиции для лечения заболеваний цнс
Hersh et al. Ibuprofen liquigel for oral surgery pain
Macleod et al. Paracetamol versus paracetamol‐codeine in the treatment of post‐operative dental pain: a randomized, double‐blind, prospective trial
Moore et al. Tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction
JP2003507420A (ja) 作用物質の組成物、クロニジンを含む前記組成物
TW202019400A (zh) 治療急性壓力症候群及創傷後壓力症候群之方法
CA2993614A1 (en) Combination therapy using acamprosate and d-cycloserine
AU2006208945A1 (en) Analgesic compositions
RS57951B1 (sr) Nova kompozicija alfentanila za tretman akutnog bola
HUP0201405A2 (en) Pharmaceutical composition for therapeutic use of melatonin
RO117147B1 (ro) Compozitie contra tusei
AU2002363874B2 (en) Use of desoxypeganine for treating clinical depression
HK40102591A (zh) 纤维肌痛的环苯紮林治疗
MX2007009968A (es) Metodo para una politerapia medicamentosa y combinaciones de medicamentos apropiadas para la misma.
AU2006228296A1 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
KR102671524B1 (ko) 구역 반사의 치료를 위한 조성물 및 요법
Saroj et al. Efficacy, safety, and costeffective analysis of low-dose etoricoxib and add-on paracetamol versus therapeutic dose etoricoxib for pain in patients after tooth extraction: a randomized interventional double-blind study
US20250322926A1 (en) Early onset response, favorable tolerability, and side effect profile in the treatment of fibromyalgia
HUP0300717A2 (hu) Mirtazapint és paracetamolt vagy nem szteroid gyulladáscsökkentő gyógyszert tartalmazó gyógyszerkombináció fejfájás kezelésére
WO2013080271A1 (ja) 鎮痛剤
Vo et al. Guidelines for the Use of Parkinsonian Drugs (in USA)
US20080090874A1 (en) Treatment of breakthrough pain in patients suffering from chronic low back pain
Tetrud Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease

Legal Events

Date Code Title Description
SREP Specification republished